Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
about
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Clinical use of Bevacizumab in treating refractory glaucomaShort-Term Topical Bevacizumab in the Treatment of Stable Corneal NeovascularizationDifferential distribution of blood and lymphatic vessels in the murine cornea.Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy.Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivoEffects of topical and subconjunctival bevacizumab in high-risk corneal transplant survivalGenetic heterogeneity of lymphangiogenesis in different mouse strainsTargeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivoAnti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityEffects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle.Corneal neovascularization: an anti-VEGF therapy review.Spontaneous lymphatic vessel formation and regression in the murine corneaQuantification of corneal neovascularization after ex vivo limbal epithelial stem cell therapy.A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Increased lymphangiogenesis and hemangiogenesis in infant corneaEffect of topical azithromycin on corneal innate immune responses.Photodynamic therapy with verteporfin for corneal neovascularizationSafety of bevacizumab on extraocular muscle in a rabbit model.Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.A Drug Delivery System for Administration of Anti-TNF-α Antibody.Evaluation of fungal keratitis using a newly developed computer program, Optscore, for grading digital corneal photographs.Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes.Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.Topical ranibizumab as a treatment of corneal neovascularizationInflammatory corneal neovascularization: etiopathogenesis.Emerging techniques to treat corneal neovascularisationThe association between corneal neovascularization and visual acuity: a systematic review.Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Current and Upcoming Therapies for Ocular Surface Chemical Injuries.Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model.Minimally invasive microneedles for ocular drug delivery.Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment.Corneal penetration of topical and subconjunctival bevacizumab.Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cellsTopical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
P2860
Q26823757-B44D7933-D22D-409E-9DE5-A164A83B3C08Q28083405-58AB4A84-BACD-4FE1-A1F1-5BE67AFCFCB1Q29999764-802F54DE-8FA3-4A08-B6B5-AAEC4DA40668Q33519478-515CB1FA-5581-4A90-9AD0-733050473894Q33774982-B122B5E0-1400-439A-B23C-8C667159744DQ33816513-56CD89D9-DFB9-4B3B-9F1F-83C264F26405Q33845555-6AF728CD-DBF0-4E57-99F1-35719F24F36EQ33947359-1E64010A-4FEB-4CD5-BFAC-EA9FFDBB452AQ34062422-73E20BED-E2F2-4E5C-AF36-B828E87950F1Q34088274-868D864F-0FED-478C-8134-FC48DD9C9980Q34493789-44DC8F53-8531-483E-BD9D-C50F5EA6CD8BQ34596341-0F8535F9-B9B8-448B-90A0-105EF76204C2Q34641522-CE7924BD-1D07-47B9-82D1-54AA80CAF6EDQ34646670-14C4FFCC-4FA2-44B7-B3C2-A4BA9AD78795Q34735822-322D7415-C360-4561-9670-EFA6889243BBQ34973743-264B1CCF-DC31-4D35-B834-BEF8962CD982Q35051497-EABB8F96-5DA0-4433-9DDD-767E01445C7AQ35684022-F1FEB8D0-FDD9-4007-BD7D-12720BBA82F5Q35964569-E719E76F-EADA-4395-A993-1B1757B4F4F6Q36128246-7FC0D764-59C3-4EA8-8BDD-5D760F8E0585Q36571709-1622C2DD-E706-4628-964B-34B944100995Q36683809-DD740402-FEB3-40E9-B73A-52FBC519CBC3Q37167446-2BAB9279-28BF-4CB4-873C-6E466D083CA3Q37218666-E5F3ADB6-E755-4302-9316-ACD3C38B477FQ37425259-B152EBA4-1139-4B68-8DF6-D8DC5B797D0EQ37549985-8B6CECD7-CF03-4210-BA64-71AA0668B053Q37573788-5D5876AA-2D49-4CC9-9651-52863CC78BAFQ37577521-60B4A2ED-8875-4BCD-B5E0-3A2AFE90F903Q37940578-7928C480-655F-495E-A349-09D6561F08D0Q37943247-3B6578A3-C381-4DD7-9AA2-B91DA42B2727Q37959022-6B4AE2FA-8D89-4AEE-BE5B-2D29B88A71B4Q38755418-0A4FE79B-8312-44AC-96B5-C1BA739BA34FQ38819339-2066A359-7932-41FF-B04B-82B0B3A6CEBEQ38908590-4F0757C3-A25D-4C9E-BFCB-19C50914EA3EQ38916649-078C7EA7-8946-4092-89D6-182D3911F900Q38958273-87AAF3ED-1D67-4DE7-AA89-48ACA426B327Q39589760-94346324-8CBC-43A5-BDB9-9DEADA70DC14Q39918424-672684B6-26BC-4DD2-93E4-23897EC86E82Q40018607-40D62D77-9556-4386-8990-199A9D23EF93Q40032771-E9427E13-1A8F-48BD-AD48-21CD069D1EF9
P2860
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@en
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@nl
type
label
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@en
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@nl
prefLabel
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@en
Topical bevacizumab in the tre ...... n-label, noncomparative study.
@nl
P2093
P2860
P1433
P1476
Topical bevacizumab in the tre ...... en-label, noncomparative study
@en
P2093
Deborah Pavan-Langston
Khalid M Al-Arfaj
Mohammad H Dastjerdi
Pedram Hamrah
Roberto Pineda
Ula V Jurkunas
P2860
P304
P356
10.1001/ARCHOPHTHALMOL.2009.18
P407
P577
2009-04-01T00:00:00Z